An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
A spokesman for Wockhardt was not available for comment.
The latest FDA action against Wockhardt comes amid a slew of regulatory rebukes this year. Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.
Indian firms, which make nearly 40 percent of generic and over-the-counter drugs for the US market, are facing more regulatory woes, including a record fine for Ranbaxy Laboratories , amid increased scrutiny by overseas regulators.
Wockhardt stock price
On November 27, 2013, at 14:10 hrs Wockhardt was quoting at Rs 427.95, down Rs 44.05, or 9.33 percent. The 52-week high of the share was Rs 2166.05 and the 52-week low was Rs 344.15.
The company's trailing 12-month (TTM) EPS was at Rs 32.23 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 13.28. The latest book value of the company is Rs 74.56 per share. At current value, the price-to-book value of the company is 5.74.
Anda sedang membaca artikel tentang
Wockhardt hit by FDA alert on Chikalthana plant
Dengan url
https://kesehatanda.blogspot.com/2013/11/wockhardt-hit-by-fda-alert-on.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Wockhardt hit by FDA alert on Chikalthana plant
namun jangan lupa untuk meletakkan link
Wockhardt hit by FDA alert on Chikalthana plant
sebagai sumbernya
0 komentar:
Posting Komentar